Trademark Overview
On Monday, March 12, 2018, a trademark application was filed for AVELAS with the United States Patent and Trademark Office. The USPTO has given the AVELAS trademark a serial number of 87831060. The federal status of this trademark filing is REGISTERED as of Tuesday, October 23, 2018. This trademark is owned by Avelas Biosciences Inc.. The AVELAS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceuticals for the treatment of cancer; pharmaceuticals for use in the fields of biotechnology and oncology; pharmaceutical products for intraoperative tumor detection, namely, an intravenously administered in vivo fluorescent protease-activatable peptide for the purpose of detecting, marking, targeting, and diagnosing cancer; pharmaceuticals, namely, activatable cell-penetrating peptides (ACPPs) and fluorescence, for the purpose of enabling image-guided surgery in the field of oncology; pharmaceutical preparations, namely, a drug delivery platform involving activatable cell-penetrating peptides (ACPPs); a drug delivery platform utilizing enzyme activation; drug delivery agents, namely, activatable cell-penetrating peptides (ACPPs) or other enzyme mediated mechanism using pathological enzymatic activity to selectively deliver imaging cargo to target tissue; pharmaceuticals to enable systemic delivery of cell-penetrating peptides (CPP) and associated cargo to cancer cells for surgi...
Biotechnology research; oncology research; research and development in the biotechnology and oncology fields; development of new technology in the field of biotechnology to enable systemic delivery of cell-penetrating peptides (CPP) and associated cargo to cancer cells; development of new biotechnology, namely, using activatable cell-penetrating peptides (ACPPs) or other enzyme mediated mechanism for surgical and therapeutic applications for cancer patients; development of new biotechnology in the field of oncology for the purpose of delivering a fluorescent, cancer-illuminating probe to detect cancer tissue; development of new biotechnology for intraoperative tumor detection; biotechnology research in connection with developing an intravenously administered in vivo fluorescent protease-activatable peptide for the purpose of detecting, marking, targeting, and diagnosing cancer; conducting clinical trials in the field of biotechnology; clinical research in the field of oncology, namely,...
